Publications by authors named "Irene Sangrador"

Neuroblastoma is a pediatric cancer that can present as low- or high-risk tumors (LR-NBs and HR-NBs), the latter group showing poor prognosis due to metastasis and strong resistance to current therapy. Whether LR-NBs and HR-NBs differ in the way they exploit the transcriptional program underlying their neural crest, sympatho-adrenal origin remains unclear. Here, we identified the transcriptional signature distinguishing LR-NBs from HR-NBs, which consists mainly of genes that belong to the core sympatho-adrenal developmental program and are associated with favorable patient prognosis and with diminished disease progression.

View Article and Find Full Text PDF
Article Synopsis
  • - Current colorectal cancer (CRC) treatments often focus on DNA-damaging agents, but they don't work for all patients, and their effects on tumor behavior are not well understood.
  • - Research using patient-derived organoids reveals that sublethal chemotherapy doses can make TP53 wildtype cancer cells enter a quiescent state, adopting a fetal-like phenotype that boosts their tumor-initiating and metastatic abilities.
  • - The presence of this fetal phenotype and nuclear YAP1 in tumors at diagnosis is linked to poor patient outcomes, suggesting that combining chemotherapy with YAP1 inhibitors may improve treatment efficacy for resistant TP53 wildtype CRC cells.
View Article and Find Full Text PDF

Ligand-dependent corepressor (LCOR) mediates normal and malignant breast stem cell differentiation. Cancer stem cells (CSCs) generate phenotypic heterogeneity and drive therapy resistance, yet their role in immunotherapy is poorly understood. Here we show that immune-checkpoint blockade (ICB) therapy selects for LCOR CSCs with reduced antigen processing/presentation machinery (APM) driving immune escape and ICB resistance in triple-negative breast cancer (TNBC).

View Article and Find Full Text PDF

The transcription factor Zeb1 has been identified as a crucial player in Kras-dependent oncogenesis. In pancreatic ductal adenocarcinoma (PDAC), Zeb1 is highly expressed in myofibroblasts and correlates with poor prognosis. As Kras mutations are key drivers in PDAC, we aimed here to assess the necessity of Zeb1 for Kras-driven PDAC and to define the role of Zeb1-expressing myofibroblasts in PDAC development.

View Article and Find Full Text PDF